Optimizing the Use of Injectable Therapies for Type 2 Diabetes

Article Type

Article

Changed

Tue, 05/03/2022 - 15:51

Display Headline

Optimizing the Use of Injectable Therapies for Type 2 Diabetes

Author(s)

Stephen A. Brunton, MD, FAAFP

The growing importance of self-injectable medications for the treatment of type 2 diabetes mellitus (T2DM) parallels that for other diseases. This is an especially significant trend, since patients are increasingly self-managing their diseases in the outpatient setting. This makes it necessary for primary care physicians to become more familiar with the role and use of injectable agents for T2DM and to overcome the negative perceptions of injectable therapies.

Article PDF

12-13_JFP_PCEC_Injectable_Therapies_Supp_for_Web_Posting.pdf

Author and Disclosure Information

Stephen A. Brunton, MD, FAAFP
Adjunct Clinical Professor
Department of Family Medicine
University of North Carolina
Chapel Hill, North Carolina
Executive Vice President for Education
Primary Care Education Consortium
Charlotte, North Carolina

Helena W. Rodbard, MD, FACP, MACE
Medical Director
Endocrinology and Metabolic Consultants
Rockville, Maryland
Past President, American Association of Clinical Endocrinologists
Past President, American College of Endocrinology

Eden M. Miller, DO
Executive Director and Co-Founder
Diabetes Nation
High Lakes Health Care
St. Charles Hospital
Bend, Oregon

Martha Funnell, MS, RN, CDE
Associate Research Scientist
Department of Medical Education
Michigan Diabetes Research and Training Center
Ann Arbor, Michigan

Edward Shahady, MD, FAAFP, ABCL
Medical Director
Diabetes Master Clinician Program FAFP/F
Fernandina Beach, Florida
Clinical Professor, Family Medicine
University of Miami and University of Florida

Issue

The Journal of Family Practice - 62(12)

Publications

MDedge Family Medicine

The Journal of Family Practice

Type 2 Diabetes ICYMI

Topics

Diabetes

Page Number

S1-S32

Sections

Medical Education Library

Supplements

Author(s)

Stephen A. Brunton, MD, FAAFP

Author(s)

Stephen A. Brunton, MD, FAAFP

Author and Disclosure Information

Stephen A. Brunton, MD, FAAFP
Adjunct Clinical Professor
Department of Family Medicine
University of North Carolina
Chapel Hill, North Carolina
Executive Vice President for Education
Primary Care Education Consortium
Charlotte, North Carolina

Helena W. Rodbard, MD, FACP, MACE
Medical Director
Endocrinology and Metabolic Consultants
Rockville, Maryland
Past President, American Association of Clinical Endocrinologists
Past President, American College of Endocrinology

Eden M. Miller, DO
Executive Director and Co-Founder
Diabetes Nation
High Lakes Health Care
St. Charles Hospital
Bend, Oregon

Martha Funnell, MS, RN, CDE
Associate Research Scientist
Department of Medical Education
Michigan Diabetes Research and Training Center
Ann Arbor, Michigan

Edward Shahady, MD, FAAFP, ABCL
Medical Director
Diabetes Master Clinician Program FAFP/F
Fernandina Beach, Florida
Clinical Professor, Family Medicine
University of Miami and University of Florida

Author and Disclosure Information

Stephen A. Brunton, MD, FAAFP
Adjunct Clinical Professor
Department of Family Medicine
University of North Carolina
Chapel Hill, North Carolina
Executive Vice President for Education
Primary Care Education Consortium
Charlotte, North Carolina

Helena W. Rodbard, MD, FACP, MACE
Medical Director
Endocrinology and Metabolic Consultants
Rockville, Maryland
Past President, American Association of Clinical Endocrinologists
Past President, American College of Endocrinology

Eden M. Miller, DO
Executive Director and Co-Founder
Diabetes Nation
High Lakes Health Care
St. Charles Hospital
Bend, Oregon

Martha Funnell, MS, RN, CDE
Associate Research Scientist
Department of Medical Education
Michigan Diabetes Research and Training Center
Ann Arbor, Michigan

Edward Shahady, MD, FAAFP, ABCL
Medical Director
Diabetes Master Clinician Program FAFP/F
Fernandina Beach, Florida
Clinical Professor, Family Medicine
University of Miami and University of Florida

Article PDF

12-13_JFP_PCEC_Injectable_Therapies_Supp_for_Web_Posting.pdf

Article PDF

12-13_JFP_PCEC_Injectable_Therapies_Supp_for_Web_Posting.pdf

The growing importance of self-injectable medications for the treatment of type 2 diabetes mellitus (T2DM) parallels that for other diseases. This is an especially significant trend, since patients are increasingly self-managing their diseases in the outpatient setting. This makes it necessary for primary care physicians to become more familiar with the role and use of injectable agents for T2DM and to overcome the negative perceptions of injectable therapies.

The growing importance of self-injectable medications for the treatment of type 2 diabetes mellitus (T2DM) parallels that for other diseases. This is an especially significant trend, since patients are increasingly self-managing their diseases in the outpatient setting. This makes it necessary for primary care physicians to become more familiar with the role and use of injectable agents for T2DM and to overcome the negative perceptions of injectable therapies.

Issue

The Journal of Family Practice - 62(12)

Issue

The Journal of Family Practice - 62(12)

Page Number

S1-S32

Page Number

S1-S32

Publications

MDedge Family Medicine

The Journal of Family Practice

Type 2 Diabetes ICYMI